PE20181357A1 - Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes - Google Patents
Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunesInfo
- Publication number
- PE20181357A1 PE20181357A1 PE2018001273A PE2018001273A PE20181357A1 PE 20181357 A1 PE20181357 A1 PE 20181357A1 PE 2018001273 A PE2018001273 A PE 2018001273A PE 2018001273 A PE2018001273 A PE 2018001273A PE 20181357 A1 PE20181357 A1 PE 20181357A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- cr6r7
- halo
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 abstract 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 abstract 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- -1 C1-6 Chemical group 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001924 cycloalkanes Chemical class 0.000 abstract 1
- 150000001925 cycloalkenes Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a un compuesto de formula (I), donde X es heteroarilo opcionalmente sustituido con uno, dos, tres o cuatro R4; Y1 es fenilo o heteroarileno C5-C6 opcionalmente fusionado con uno o dos anillos seleccionados entre cicloalcano C3-C8, cicloalqueno C3-C8, entre otros; donde Y1 esta opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados de R5, OR5, SR5, entre otros; L1 es (CR6R7)q, (CR6R7)s,-O-(CR6R7)r, entre otros; Y2 es C3-C11 de cadena ramificada, cicloalquilo C3-C7, cicloalquenilo C4-C7, entre otros. Y2 esta opcionalmente sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados de R8, OR8, SR8, entre otros; Z1 es C(O)OR9, C(O)NR10R11, C(O)R11, entre otros; R1 es halo, R2 es deuterio, halo, C1-C6 alquilo, entre otros; R3 es halo, C1-6, alquilo, entre otros; R4 es CN, NO2, halogeno, entre otros; R5 es alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, entre otros; R6 y R7 son H, R15, OR15, entre otros; R8 es C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, entre otros; R9 es alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, entre otros; R10 y R11 son H, alquilo C1-C6, alquenilo C2-C6, entre otros; R15 es alquilo C1-C4; alquenilo C2-C4, alquinilo C2-C4, entre otros; q es 1, 2 o 3; s, r y m son 0, 1, 2 o 3 donde la suma de s y r es 0, 1 o 2; m es 0, 1, 2 o 3; n es un numero del 0-6 y p es 0, 1 o 2. Tambien se refiere a una composicion farmaceutica. Dichos compuestos inhiben la actividad de las proteinas antiapoptoticas Bcl-xL y son utiles para el tratamiento del cancer tales como el cancer de vejiga, cancer de cerebro, cancer de mama, entre otros
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547165P | 2011-10-14 | 2011-10-14 | |
| CN2012078372 | 2012-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181357A1 true PE20181357A1 (es) | 2018-08-22 |
Family
ID=47073545
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001273A PE20181357A1 (es) | 2011-10-14 | 2012-10-11 | Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes |
| PE2014000520A PE20141997A1 (es) | 2011-10-14 | 2012-10-11 | Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000520A PE20141997A1 (es) | 2011-10-14 | 2012-10-11 | Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP3266776A1 (es) |
| JP (2) | JP6049738B2 (es) |
| KR (1) | KR102056587B1 (es) |
| CN (1) | CN109535155B (es) |
| AR (1) | AR088328A1 (es) |
| AU (2) | AU2012322818A1 (es) |
| BR (1) | BR112014009052B1 (es) |
| CA (1) | CA2850976C (es) |
| CL (1) | CL2014000922A1 (es) |
| CO (1) | CO6950477A2 (es) |
| DO (1) | DOP2014000074A (es) |
| EC (1) | ECSP14000606A (es) |
| ES (1) | ES2699966T3 (es) |
| IL (1) | IL231926A (es) |
| MX (2) | MX364950B (es) |
| PE (2) | PE20181357A1 (es) |
| PH (1) | PH12014500815B1 (es) |
| RU (1) | RU2594282C2 (es) |
| SG (2) | SG10201606031XA (es) |
| TW (1) | TWI561521B (es) |
| UY (1) | UY34381A (es) |
| WO (1) | WO2013055895A1 (es) |
| ZA (1) | ZA201402555B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| AU2015360621A1 (en) * | 2014-12-09 | 2017-06-29 | Abbvie Inc. | Bcl-xL inhibitory compounds and antibody drug conjugates including the same |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| WO2017107089A1 (en) * | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2019000236A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| JP2022526450A (ja) * | 2019-04-12 | 2022-05-24 | トニックス ファーマシューティカルズ ホールディング コーポレーション | Ｃｄ４０－ｃｄ１５４結合の阻害剤 |
| KR102316961B1 (ko) * | 2020-01-29 | 2021-10-26 | 프라비바이오 주식회사 | 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물 |
| JP2023553811A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用方法 |
| CN117794929A (zh) | 2021-02-02 | 2024-03-29 | 法国施维雅药厂 | 选择性bcl-xl protac化合物及使用方法 |
| IL317101A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of anticancer compounds and methods of using them |
| KR20250027281A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법 |
| CN119562832A (zh) | 2022-05-20 | 2025-03-04 | 诺华股份有限公司 | Met bcl-xl抑制剂抗体-药物缀合物及其使用方法 |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| JPH11512429A (ja) | 1995-09-15 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | アミノアリールオキサゾリジノン ｎ−オキシド |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US7307163B2 (en) | 2004-04-19 | 2007-12-11 | Symed Labs Limited | Process for the preparation of linezolid and related compounds |
| RU2388751C2 (ru) * | 2004-07-15 | 2010-05-10 | Амр Текнолоджи, Инк. | Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| ATE429423T1 (de) | 2004-07-20 | 2009-05-15 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| US7402596B2 (en) * | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008098857A1 (en) | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| EP2148867B1 (en) | 2007-04-19 | 2014-09-10 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| MX2011006509A (es) * | 2008-12-19 | 2011-10-19 | Genentech Inc | Compuestos heterociclicos y métodos de uso. |
| ES2462715T3 (es) * | 2008-12-19 | 2014-05-26 | Genentech, Inc. | Compuestos y métodos de uso |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| TWI571466B (zh) | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
-
2012
- 2012-10-08 TW TW101137132A patent/TWI561521B/zh not_active IP Right Cessation
- 2012-10-10 UY UY0001034381A patent/UY34381A/es unknown
- 2012-10-11 EP EP17185702.2A patent/EP3266776A1/en not_active Withdrawn
- 2012-10-11 EP EP12778012.0A patent/EP2768830B1/en active Active
- 2012-10-11 JP JP2014535867A patent/JP6049738B2/ja not_active Expired - Fee Related
- 2012-10-11 PE PE2018001273A patent/PE20181357A1/es unknown
- 2012-10-11 WO PCT/US2012/059717 patent/WO2013055895A1/en not_active Ceased
- 2012-10-11 SG SG10201606031XA patent/SG10201606031XA/en unknown
- 2012-10-11 SG SG11201401479SA patent/SG11201401479SA/en unknown
- 2012-10-11 CA CA2850976A patent/CA2850976C/en active Active
- 2012-10-11 AU AU2012322818A patent/AU2012322818A1/en not_active Abandoned
- 2012-10-11 MX MX2017014059A patent/MX364950B/es unknown
- 2012-10-11 MX MX2014004561A patent/MX351970B/es active IP Right Grant
- 2012-10-11 BR BR112014009052-1A patent/BR112014009052B1/pt not_active IP Right Cessation
- 2012-10-11 PH PH1/2014/500815A patent/PH12014500815B1/en unknown
- 2012-10-11 CN CN201910042347.5A patent/CN109535155B/zh not_active Expired - Fee Related
- 2012-10-11 KR KR1020147012847A patent/KR102056587B1/ko not_active Expired - Fee Related
- 2012-10-11 RU RU2014119254/04A patent/RU2594282C2/ru active
- 2012-10-11 ES ES12778012T patent/ES2699966T3/es active Active
- 2012-10-11 PE PE2014000520A patent/PE20141997A1/es active IP Right Grant
- 2012-10-12 AR ARP120103812A patent/AR088328A1/es not_active Application Discontinuation
-
2014
- 2014-04-03 IL IL231926A patent/IL231926A/en active IP Right Grant
- 2014-04-08 ZA ZA201402555A patent/ZA201402555B/en unknown
- 2014-04-11 CL CL2014000922A patent/CL2014000922A1/es unknown
- 2014-04-11 DO DO2014000074A patent/DOP2014000074A/es unknown
- 2014-05-07 CO CO14097119A patent/CO6950477A2/es unknown
- 2014-05-13 EC ECIEPI2014606A patent/ECSP14000606A/es unknown
-
2016
- 2016-11-22 JP JP2016226799A patent/JP6337068B2/ja active Active
-
2017
- 2017-07-17 AU AU2017206149A patent/AU2017206149B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181357A1 (es) | Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes | |
| CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
| DOP2016000140A (es) | Inhibidores de syk | |
| MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| PE20181491A1 (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| ECSP17002135A (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| MX2015008196A (es) | Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana. | |
| PE20150886A1 (es) | Compuestos de benceno sustituidos | |
| UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CO6640274A2 (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| EA201791094A1 (ru) | Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки | |
| AR101177A1 (es) | Inhibidores de la syk | |
| UY35146A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| UY35400A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201491623A1 (ru) | Замещенные пирролидин-2-карбоксамиды | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina | |
| EA202190167A1 (ru) | Замещенные фенилоксазолидиноны для антимикробной терапии |